These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10649982)

  • 41. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity.
    Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR
    ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
    Hirokawa Y; Morie T; Yamazaki H; Yoshida N; Kato S
    Bioorg Med Chem Lett; 1998 Mar; 8(6):619-24. PubMed ID: 9871571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-Arylpiperazinylethyl-1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione derivatives as novel, high-affinity and selective alpha(1)-adrenoceptor ligands.
    Pittalà V; Romeo G; Salerno L; Siracusa MA; Modica M; Materia L; Mereghetti I; Cagnotto A; Mennini T; Marucci G; Angeli P; Russo F
    Bioorg Med Chem Lett; 2006 Jan; 16(1):150-3. PubMed ID: 16216506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
    Zajdel P; Marciniec K; Maślankiewicz A; Grychowska K; Satała G; Duszyńska B; Lenda T; Siwek A; Nowak G; Partyka A; Wróbel D; Jastrzębska-Więsek M; Bojarski AJ; Wesołowska A; Pawłowski M
    Eur J Med Chem; 2013 Feb; 60():42-50. PubMed ID: 23279866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
    Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L
    J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bivalent molecular probes for dopamine D2-like receptors.
    Huber D; Löber S; Hübner H; Gmeiner P
    Bioorg Med Chem; 2012 Jan; 20(1):455-66. PubMed ID: 22100258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
    Kolasa T; Matulenko MA; Hakeem AA; Patel MV; Mortell K; Bhatia P; Henry R; Nakane M; Hsieh GC; Terranova MA; Uchic ME; Miller LN; Chang R; Donnelly-Roberts DL; Namovic MT; Hollingsworth PR; Martino B; El Kouhen O; Marsh KC; Wetter JM; Moreland RB; Brioni JD; Stewart AO
    J Med Chem; 2006 Aug; 49(17):5093-109. PubMed ID: 16913699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
    Grundt P; Prevatt KM; Cao J; Taylor M; Floresca CZ; Choi JK; Jenkins BG; Luedtke RR; Newman AH
    J Med Chem; 2007 Aug; 50(17):4135-46. PubMed ID: 17672446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
    TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
    J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
    [No Abstract]   [Full Text] [Related]  

  • 51. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
    Noda-Saita K; Matsumoto M; Hidaka K; Hatanaka K; Ohmori J; Okada M; Yamaguchi T
    Biochem Biophys Res Commun; 1999 Feb; 255(2):367-70. PubMed ID: 10049714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
    Tu Z; Li S; Cui J; Xu J; Taylor M; Ho D; Luedtke RR; Mach RH
    J Med Chem; 2011 Mar; 54(6):1555-64. PubMed ID: 21348515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D
    Chen PJ; Taylor M; Griffin SA; Amani A; Hayatshahi H; Korzekwa K; Ye M; Mach RH; Liu J; Luedtke RR; Gordon JC; Blass BE
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2690-2694. PubMed ID: 31387791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.
    Mach RH; Huang Y; Freeman RA; Wu L; Vangveravong S; Luedtke RR
    Bioorg Med Chem Lett; 2004 Jan; 14(1):195-202. PubMed ID: 14684327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of mixed D2/5-HT1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines.
    Roglić G; Dukić-Stefanović S; Andrić D; Kostić-Rajacić S; Soskić V
    Pharmazie; 2001 Oct; 56(10):803-7. PubMed ID: 11683128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
    el Ahmad Y; Laurent E; Maillet P; Talab A; Teste JF; Dokhan R; Tran G; Ollivier R
    J Med Chem; 1997 Mar; 40(6):952-60. PubMed ID: 9083484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
    Ghosh B; Antonio T; Gopishetty B; Reith M; Dutta A
    Bioorg Med Chem; 2010 Aug; 18(15):5661-74. PubMed ID: 20605099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introduction of a methyl group in alpha- or beta-position of 1-heteroarylethyl-4-phenylpiperazines affects their dopaminergic/serotonergic properties.
    Roglic G; Andric D; Kostic-Rajacic S; Dukic S; Soskic V
    Arch Pharm (Weinheim); 2001 Dec; 334(12):375-80. PubMed ID: 11852532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.